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Abstract 
Background: Esophageal squamous cell carcinoma (ESCC) is a highly lethal cancer, and its underlying molecular 
mechanisms are poorly understood. Recent large‑scale genome‑wide association studies in Chinese Han populations 
have identified an ESCC susceptibility locus within the SLC39A6 gene. Here, we sought to explore the expression and 
biological function of SLC39A6 in ESCC.
Methods: Multiethnic validation of SLC39A6 protein expression was performed in different cohorts of patients from 
Chinese Han and Kazakh populations in the Xinjiang region by immunohistochemistry. The associations among 
SLC39A6 expression, clinicopathological parameters, and prognosis outcomes of ESCC were analyzed. And the effects 
of SLC39A6 silencing by siRNA on cell proliferation, apoptosis, and invasiveness, as well as the proteins involved in 
epithelial‑to‑mesenchymal transition (EMT) of esophageal cancer cells, were studied.
Results: SLC39A6 protein expression increased progressively from normal esophageal epithelium (NEE) to low‑grade 
intraepithelial neoplasia to ESCC, and finally reached the highest in high‑grade intraepithelial neoplasia from Han 
ethnic. Similarly, SLC39A6 protein was significantly overexpressed in Kazakh ethnic ESCC compared with that in NEE. 
Increased expression of SLC39A6 was found to be closely correlated with histological grade and early Tumor‑Node‑
Metastasis stage I/II. High tumorous SLC39A6 expression was significantly correlated with shorter overall survival (OS). 
Cox regression analysis confirmed that SLC39A6 expression was an independent prognostic factor for poor OS in 
ESCC. Experimentally, the suppression of SLC39A6 expression promoted ESCC cell apoptosis but abrogated prolifera‑
tion and invasion, and induced an EMT phenotype that included enhanced expression of E‑cadherin, loss of vimentin, 
and morphological changes in ESCC cells in vitro.
Conclusions: Combined, our findings highlight a tumor‑promoting role for SLC39A6 in ESCC, suggesting that 
SLC39A6 could serve as an early detector of high‑risk subjects and prognostic biomarker. The targeting of SLC39A6 
might be a potential therapeutic strategy for blocking ESCC.
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Background
Esophageal squamous cell carcinoma (ESCC), a major 
histological type of esophageal cancer in East Asian 
countries, is one of the most lethal cancers in the world 
[1–3]. ESCC ranks the sixth in mortality and the seventh 
in incidence in China with great variations in geography, 
ethnicity, and socio cultures [4]. Despite the development 
of multimodal therapies, including surgery, chemother-
apy, and chemoradiotherapy, the prognosis of patients 
remains poor. The long-term outcome of this cancer is 
still dismal, with 5-year survival rates of around 30 % [5, 
6]. In contrast, the 5-year survival rate of early esopha-
geal cancer is higher than 90 % [7]. Although a variety of 
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molecular alterations have been identified over the last 
two decades [8, 9], sensitive and specific biomarkers for 
early diagnosis and accurate indicators for ESCC prog-
nosis are currently unavailable. It is imperative, there-
fore, to identify novel biomarkers for early detection and 
therapeutic targets if long-term survival of ESCC is to be 
improved.
A large-scale genome-wide association study (GWAS) 
of a Chinese Han populations recently identified a new 
ESCC susceptibility locus at chromosome 18q12.2, 
tagged by a non-synonymous SNP of rs7242481, which 
is located in the 5′UTR in SLC39A6 [10]. SLC39A6, also 
known as LIV-1, belongs to a new subfamily of Zrt, Irt-
like protein zinc transporters (LZTs) [11]. It is involved in 
maintaining the intracellular homeostasis of zinc, an ion 
that is essential in the control of cellular growth and dif-
ferentiation [12]. SLC39A6 plays a critical role in main-
taining zinc homeostasis, and was originally identified 
as an estrogen-induced gene in a breast cancer cell line 
[13]. Generally, elevated SLC39A6 expression is report-
edly related to cancer progression in other various types 
of cancer, including breast [13, 14], prostate [15], pan-
creatic [16], cervical [17] and liver cancers [18]. Con-
versely, controversial data on the SLC39A6 expression 
have also been reported in many cancers, such as breast 
cancer. The reports from the Grattan et  al. found that 
SLC39A6 expression is positively associated with metas-
tasis to regional lymph nodes [13], whereas Kasper et al. 
reported that SLC39A6 expression is associated with 
a positive outcome in breast cancer patients [19]. The 
findings suggested that the correlation of SLC39A6 and 
prognosis might vary in similar malignancies because 
of population heterogeneity, so whether it is elevated or 
suppressed in tumors is dependent on the types and con-
texts of cancers.
In the case of ESCC, SLC39A6 has received relatively 
little attention. Evidence for its potential utility as a 
target gene for prognosis and treatment of esophageal 
cancer is lacking. Although only one large-scale GWAS 
reported SLC39A6 as the susceptibility gene of ESCC 
and the expression level in a Chinese Han population 
[10], no other report has discussed the expression of 
SLC39A6 in precursor lesions and other ethnic patients 
with esophageal carcinoma. Therefore, more studies are 
necessary to characterize the expression of SLC39A6 
during the multi-stage development of esophageal can-
cer, and determine its prognostic value. In addition, 
most current studies demonstrated that SLC39A6, as 
an obligatory co-factor, has a crucial role in regulating 
epithelial–mesenchymal transition (EMT) in pancreatic 
[16] and prostate cancers [15], causing cancer cell migra-
tion. However, the roles of SLC39A6 in ESCC have not 
yet been characterized.
In this study, we sought to investigate the expression 
pattern of SLC39A6 in ESCC patients of two different 
ethnicities and its precursor lesions tissues, and charac-
terize the underlying biological function of SLC39A6 in 
ESCC cells. We not only discovered that SLC39A6 could 
serve as an early detector of high-risk subjects and prog-
nostic biomarker, but also discovered the tumor-promot-
ing role of SLC39A6 in regulating ESCC progression and 
metastasis via inducing an EMT phenotype. The target-
ing of SLC39A6 might be a potential therapeutic strategy 




Tissue microarrays (TMAs) were used for immunostain-
ing of SLC39A6 in two independent cohorts of ESCC. 
One cohort comprised 142 Han ethnic patients with 
ESCC collected between 1997 and 2013 from the First 
University Hospital, Shihezi University School of Medi-
cine. The other cohort comprised 86 Kazakh ethnic 
patients with ESCC collected between 1984 and 2011 
from the First University Hospital, Shihezi University 
School of Medicine, Xinjiang Yili Prefecture Friend-
ship Hospital and People’s Hospital of Xinjiang Uyghur 
Autonomous Region. No restrictions were placed in 
terms of age, sex, or disease stage. None of the patients 
received prior surgery other than diagnostic biopsies, 
chemotherapy, or radiation therapy. Clinical data were 
collected on clinicopathologic variables, such as tumor 
differentiation and lymph node metastasis. All cases with 
pathologic diagnoses for tumor-node-metastasis (TNM) 
stages were evaluated according to Cancer Stage Manual, 
7th Edition, issued in 2009 by the American Joint Com-
mittee on Cancer (AJCC/UICC). Clinical characteris-
tics of patients from both validation centers are listed 
in Table  1. As expected, most patients who underwent 
surgery in both centers were men. However, some nota-
ble differences in clinical characteristics were observed 
between the two centers. Patients from the Han ethnic 
group were slightly older than those in the Kazakh ethnic 
group (age 58.0 vs. 63.5 years; P < 0.001). More patients 
in the Kazakh ethnic cohort had lymph node metastasis 
compared with patients in the Han ethnic group (56.98 
vs. 34.51 %; P < 0.001) (Table 1).
A total of 142 Han ethnic cancer tissues combined 
with its 133 adjacent mucosa and 132 distant normal 
mucosa and 86 Kazakh ethnic cancer tissues with its 41 
distant normal mucosa were removed immediately after 
surgery, fixed in 10 % formalin, and embedded in paraf-
fin. Approximately 133 precursor lesions in the adjacent 
mucosa were selected and classified as 81 low-grade 
intraepithelial neoplasia (LGIN) and 52 high-grade 
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intraepithelial neoplasia (HGIN) (Additional file  1: Fig-
ure S1). All the cases were diagnosed by two patholo-
gists. Clinical and pathological data of all patients were 
obtained from medical records. Follow-ups were con-
ducted on 75 Han patients, with a follow-up deadline of 
10 July 2014. The clinical-pathological characteristics of 
75 esophageal cancer patients with follow-up  informa-
tion were presented in the Additional file 2: Table S1.
SLC39A6 expression detected by immunohistochemistry 
(IHC) using TMAs
Paraffin-embedded materials were sampled from 228 
(142 Han, 86 Kazakh) formalin-fixed esophageal cancer 
tissues, 133 precursor lesion tissues, and 173 (132 Han, 
41 Kazakh) normal tissue samples with 0.6 mm-diameter 
tissue cores using a tissue arrayer (ALPHELYS, Plaisir, 
France). Slides were stained according to the manufac-
turers’ protocols for SLC39A6 (14236-1-AP: Proteintech 
Group Inc., Chicago, USA) which was a rabbit poly-
clonal anti-SLC39A6/LIV1 antibody and was consist-
ent  with  the  previously described  report [10]. In brief, 
paraffin-embedded 4  µm sections were baked at 65  °C 
for 60  min and then rehydrated using graded alcohols, 
as previously described. Each 4  μm tissue section was 
deparaffinized and rehydrated. The sections were auto-
claved in 1  mM ethylenediaminetetraacetic acid buffer 
(pH 9.0) at 130  °C for 10 min for anti-SLC39A6, cooled 
to 30 °C for 40 min, and incubated with fresh 3 % H2O2 
in methanol for 10  min at room temperature. Tissue 
sections were then incubated at 4  °C overnight with 
anti-SLC39A6 rabbit polyclonal antibody at a dilution 
of 1:2400 in PBS containing 1 % bovine serum albumin, 
washed in PBS, and incubated with secondary antibody 
for 30 min at 37 °C. Subsequently, 3,3-diaminobenzidine 
was employed to visualize SLC39A6 antibody binding, 
and the tissue sections were counterstained with hema-
toxylin. In addition, negative controls were performed 
using PBS instead of the SLC39A6 antibody.
Semi‑quantitative assessment and scoring
The expression of SLC39A6 was scored semi-quantita-
tively according to the percentage of positive cells and 
cytoplasmic/nuclear staining intensity. The percentage 
of positively stained cells was as follows: 0 (<5 % positive 
cells), 1 (6–25 % positive cells), 2 (26–50 % positive cells), 
3 (51–75 % positive cells), or 4 (>75 % positive cells). The 
cytoplasmic/nuclear staining intensity was categorized 
as follows: 0 score, negative; 1 score, buff; 2 score, yel-
low; and 3 score, brown. The percentage of positive epi-
thelial cells and staining intensities were then multiplied 
to obtain the immunoreactivity score (IS) for each case. 
For example, if the staining intensity was brown (3) and 
the percentage of positive cells was greater than 45 % (2), 
then the IS would be 3 × 2 = 6. Two pathologists inde-
pendently reviewed five random fields from each sample 
slide. Cases with discrepant scores were reviewed using 
a 10-headed microscope and re-assigned a consen-
sus score. Thus, the IS range was from 0 to 12. Optimal 
cut-off values for this assessment system were identi-
fied as follows: high expression of SLC39A6 was defined 
as an expression index score of 5, and low expression of 
SLC39A6 was defined as an expression index score of < 5. 
These cases were divided into two groups based on their 
IS of SLC39A6 staining. Cases with a score of ≥5 were 
categorized as the high expression group, and cases with 
a score of <5 were categorized as the low expression 
group.
Cell lines and culture conditions
Four esophageal cancer cell lines (Eca109, EC9706, TE-1, 
and KYSE-150) and a normal esophageal epithelium 
(NEE) cell line (HEEC) were purchased from the Institute 
of Biochemistry and Cell Biology of the Chinese Acad-
emy of Sciences (Shanghai, China). Cells were cultured 
in RPMI 1640 or DMEM (GIBCO-BRL) supplemented 
with 10 % fetal bovine serum, 100 U/mL penicillin, and 
100 mg/mL streptomycin in humidified air at 37 °C with 
5 % CO2.
Table 1 Demographic and  clinical characteristics 
of patients in validation cohorts
P < 0.05 indicates a significant association among the variables
Characteristic Han ethnic Kazakh ethnic P value
(N = 142) (N = 86)
No. % No. %
Age at surgery, years <0.001
 Median 63 58
 Range 36–81 34–73
Sex 0.028
 Male 107 75.35 53 61.63
 Female 35 24.65 33 38.37
Differentiation 0.316
 Well 39 27.46 21 24.42
 Moderate 74 52.11 53 61.63
 Poor 29 20.42 12 13.95
Lymph node metastasis 0.001
 No 93 65.49 37 43.02
 Yes 49 34.51 49 56.98
TNM 0.485
 I + II 94 66.2 53 61.63
 III + IV 48 33.8 33 38.37
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Small interfering RNA (siRNA)‑based knockdown
Oligonucleotide siRNA duplexes were synthesized 
by Invitrogen (Carlsbad, USA). The following siRNA 
sequence for SLC39A6 was used: 5′-UUC CAU UGC 
UGG UUC UUC AUG GCU A-3′. A non-target scram-
bled siRNA was used as the negative control: 5′-UUC 
UCC GAA CGU GUC ACG UTT-A-3′. The cells were 
transfected with 50  nM siRNA targeting SLC39A6 or 
RNAi negative control duplexes using HiPerFect trans-
fection reagents (Qiagen, Hilden, Germany) in serum-
free conditions according to the Quick-StartProtocol.
Western blot analysis
Western blot analyses were performed on cell lysates pre-
pared from Eca109 and EC9706 cell lines as described 
previously. Transfected cells were lysed in RIPA lysis 
buffer (Solarbio). Cell protein lysates were separated 
by 10  % SDS-polyacrylamide gel electrophoresis. Pro-
teins were transferred to PVDF membranes (Immobilon 
0.45  μm, Millipore, USA), and immersed in a blocking 
solution containing 5  % non-fat milk and 0.1  % Tween-
20 for 1  h. After blocking, membranes were incubated 
with primary antibodies overnight at 4  °C and then 
with secondary antibodies for 2 h at room temperature. 
After washing, the resulting bands were visualized using 
the standard ECL procedure, quantified by densitom-
etry, and normalized to the corresponding β-actin bands. 
The following antibodies were also used: anti-SLC39A6 
(14236-1-AP: Proteintech Group Inc., Chicago, USA), 
anti-β-actin (sc-47778, Santa Cruz, Santa Cruz, CA, 
USA). Antibodies against E-cadherin, Vimentin were 
purchased from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA, USA).
In vitro cell growth assay
Cell growth was measured by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. 
Cells (4 × 103) were seeded at each well of 96-well flat-
bottom plates (NUNC). After culturing for 24, 48, 72, 
96, and 120  h, cells were stained with 20 μL of sterile 
MTT dye (5 mg/mL, Solarbio) for 4 h at 37 °C. The cul-
ture medium was removed, and 150  μL of DMSO was 
added. The 96-well plates were shaken until the formazan 
crystals dissolved completely. The absorbance value was 
measured on a microplate reader (Bio-Rad) at 490 nm.
Cell apoptosis assay
Cell apoptosis was analyzed by flow cytometry. Cells 
were cultured in 24-well plates. At 48 h after transfection, 
cells were removed from the plate using a trypsin diges-
tion solution, collected, and resuspended in 500  µL of 
1 × binding buffer. After the addition of 5 µL of Annexin 
V-FITC to each well, cells were incubated in the dark for 
5 min. An aliquot of 10 µL of PI was added to each well, 
followed by additional incubation in the dark for 5 min. 
Finally, flow cytometry was performed.
Colony formation assay
Cells (3 × 103) were plated in six-well plates for 14 days 
at 37 °C. The cells were washed with 1 mL of PBS, fixed 
with 4 % paraformaldehyde for 15 min, stained with 0.1 % 
crystal violet for 20 min, and finally washed three times 
with 1 mL of water. The number of colonies was manually 
counted.
Matrigel invasion assay
The Matrigel invasion membrane (BD BioCoat Matrigel 
Invasion Chamber; BD Biosciences) was rehydrated. 
Cells were added to a Matrigel invasion chamber in trip-
licate and then incubated for 8 h. After noninvading cells 
were removed, the membranes containing the invading 
cells were stained with DAPI.
Statistical analysis
All statistical analyses were performed using SPSS (IBM 
Corp., Armonk, NY, USA) version 17.0. To compare dif-
ferences in demographic and clinical factors between the 
two validation cohorts, t test was used for continuous 
variables, and χ2 test and Fisher’s exact test were used 
for categorical variables. The Chi square test or Fisher’s 
exact test were used to evaluate the associations between 
SLC39A6 expression and clinicopathological features. 
McNemar test was used to assess the difference in the 
proportion of samples with high level of the SLC39A6 
protein between the ESCC and their corresponding 
LGIN and HGIN tissues in Chinese Han population. 
Receiver operating characteristic (ROC) curves analysis 
and the area under the curve (AUC) were used to evalu-
ate the specificity and sensitivity of ESCC and esophageal 
squamous intraepithelial neoplasia (ESIN). Correlations 
between prognostic outcomes and SLC39A6 expres-
sion were investigated using Kaplan–Meier analysis and 
the Cox proportional hazards model. The significance of 
prognostic factors on survival was studied by Cox regres-
sion model. Data points are reported as experimental 
average, and error bars represent SD. For the variables, 
a P value of less than 0.05 was considered statistically 
significant.
Results
Upregulation of SLC39A6 in precancerous lesions and ESCC 
tissues and cell lines
During the multi-stage development of ESCC in the 
Chinese Han population, IHC analysis showed that the 
frequency of SLC39A6 protein overexpression was low-
est in normal samples (14.39 %) and increased gradually 
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during the evolution of esophageal carcinogenesis, 
with 51.85  % (42/81) of LGIN and 76.47  % (39/52) of 
HGIN, and a slight decrease at 66.90  % (95/142) of 
ESCC but still showing high SLC39A6 protein expres-
sion. In NEE, SLC39A6 labeling was weak and pre-
dominantly expressed in the cytoplasm of basal cells 
and suprabasal layer cells (Fig.  1a); however, SLC39A6 
was highly expressed in HGIN and ESCC cells with the 
signal strongest in nuclei/cytoplasm (Fig.  1b, c). Box-
plot showed that the trend of SLC39A6 immunoreactiv-
ity score increased in a stepwise manner from normal, 
LGIN, and ESCC, and peaked in HGIN using the t tests 
(Fig. 1d). In addition, the four level score (0–1, 2–4, 5–8, 
and 9–12) distribution of SLC39A6 protein expression in 
normal, precancerous lesions, and ESCC was significantly 
distinct (Fig.  1e). Furthermore, as shown in Table 2, in-
depth analysis using the Chi square test revealed that 
the overexpression rates of SLC39A6 protein increased 
significantly in LGIN, HGIN, and ESCC compared with 
normal tissues (P  <  0.001). Significant differences were 
also observed between LGIN and HGIN (P = 0.004), as 
well as between LGIN and ESCC (P  =  0.037), whereas 
no significant differences were found between LGIN and 
ESCC (P > 0.05, Table 2). However, using the McNemar 
test, we did not found the SLC39A6 expression signifi-
cantly differs between ESCC and their corresponding 
HGIN tissues (P = 0.076); similarly, the SLC39A6 expres-
sion also does not significantly differ between ESCC and 
their corresponding LGIN tissues (P = 0.229; Additional 
file 3: Table S2).
SLC39A6 protein expression was then externally vali-
dated in the cohort of patients from the Kazakh ethnic 
group (Table 3). As shown in Fig. 2, the negative controls 
for the normal tissues (Fig.  2a) and esophageal cancer 
(Fig.  2b) specimens were negative. Consistent with the 
results of IHC analysis of SLC39A6 protein alteration 
in Han ethnic, SLC39A6 expression was upregulated in 
68/86 (79.07  %) of ESCC specimens, and only in 14/41 
(34.15 %) in normal samples (Fig. 2c, d). The expression 
levels of SLC39A6 protein in ESCC tissues were signifi-
cantly higher than those in the corresponding normal tis-
sues in the Kazakh population (P < 0.001, Fig. 2e). These 
findings are in accordance with the results from the Han 
population. The results indicate no difference in terms of 
the staining pattern and frequency of SLC39A6 protein 
expression between different racial tissues types collected 
from the Chinese Han and Kazakh populations, as well as 
those residing in western China.
We then examined the expression of SLC39A6 pro-
tein in NEE cell line (HEEC) and ESCC cells by West-
ern blotting. Interestingly, we carefully checked 
the X-ray film and found that all of the lanes of the 
SLC39A6 protein from the cell lines exhibit two bands, 
particularly at 68 and 103  kDa. Full-length SLC39A6, 
as the pro-protein, is predicted to be 85 kDa and pro-
duces a 103 kDa band, but this band would be reduced 
to 68  kDa when SLC39A6 is activated by N-terminal 
cleavage which triggers SLC39A6 plasma membrane 
location and zinc influx [20]. Similarly, as shown in 
Fig.  2F, all esophageal cancer cell lines expressed high 
levels of modified SLC39A6 protein (68 kDa) compared 
with NEE cell. Aberrant SLC39A6 expression in both 
ESCC tissues and ESCC cells suggests that increased 
SLC39A6 expression might be associated with tumor 
progression.
Correlation of SLC39A6 expression with clinicopathologic 
characteristics
We further determined the association between 
SLC39A6 expression and clinicopathological parameters 
of ESCC from the two different populations (Table 4). The 
expression of SLC39A6 was positively correlated with 
the histological grade in the Chinese Han and Kazakh 
populations (PHan  =  0.018, PKazakh  =  0.003, respec-
tively). The staining pattern and frequency of SLC39A6 
expression were weakly related to lymph node metasta-
sis (p =  0.050), but the effects did not reach significant 
statistic level. By contract, no significant correlations 
with age, gender, primary tumor sites, and TNM stage 
were observed in the Chinese Han ethnic group. When 
the clinical stage of ESCC in patients was classified into 
stage I to IV according to the TNM classification, stage 
I and II tumors showed significantly higher percentages 
of SLC39A6-positive cells compared with stages III and 
IV tumors in the Kazakh population (P = 0.026). No sta-
tistically significant relationship was observed between 
SLC39A6 expression and other clinicopathologic charac-
teristics (P > 0.05).
Sensitivity and specificity values of SLC39A6 in ESCC
Using the distant normal mucosa as the control, the 
receiver operating characteristic (ROC) curves for vari-
ous types of tissues clearly illustrate the point on the 
curve closest to (0.0, 1.0), which maximizes both sensi-
tivity and specificity for ESCC, HGIN, and LGIN. The 
score with the most areas under the ROC curve (AUC) 
and having both maximum “sensitivity” and “1-specific-
ity” was selected as the cut-off score. We found that the 
immunohistochemical cut-off scores of SLC39A6 easily 
distinguished the ESCC, HGIN, and LGIN tissues from 
the normal esophageal tissues, all of which demonstrated 
high sensitivity and specificity values according to the 
area under ROC curve (all >0.7, Fig. 3; Additional file 4: 
Table S3). These results support the notion that SLC39A6 
may be a potential diagnostic biomarker for ESCC and 
ESIN.
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Fig. 1 Immunohistochemical analysis of SLC39A6 in non‑tumor esophageal, precancerous lesions, and ESCC tissues from Chinese Han ethnic. Rep‑
resentative SLC39A6 immunostaining in a non‑tumor esophageal (top panel magnification ×40; middle panel magnification ×100; bottom panels 
magnification ×200), precancerous lesions. b LGIN and HGIN (top panel magnification ×40; middle panel magnification ×100; bottom panels magni‑
fication ×200), and c ESCC tissues (top panel magnification ×40; middle panel magnification ×100; bottom panels magnification ×200). d SLC39A6 
immunoreactivity was scored in human normal esophageal squamous epithelium, precancerous lesions, and ESCC tissues. (*p < 0.05; **p < 0.01; 
***p < 0.001). e The four level score (0–1, 2–4, 5–8, and 9–12) distribution of SLC39A6 protein expression in normal, precancerous lesions, and ESCC
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SLC39A6 overexpression predicts poor prognosis in ESCC
The association between SLC39A6 protein expres-
sion and overall survival (OS) of ESCC was estimated 
using log-rank test and multivariable Cox proportional 
hazard regression analysis. Of the 142 ESCC patients 
examined from the Han ethnic, clinical follow-up infor-
mation was available for 75 patients. The median sur-
vival time of patients with lower SLC39A6 expression 
was 38.21  months (range 1–96  months), whereas that 
of patients with SLC39A6 overexpression was only 
12.18 months (range 1–78 months). As shown in Fig. 4a, 
Kaplan–Meier survival analysis showed that ESCC 
patients with higher expression of SLC39A6 protein 
had significantly worse prognosis than ESCC patients 
with low or no expression (log-rank test, χ2  =  6.749, 
P  =  0.009). Patients with SLC39A6 overexpression 
had worse OS and greater risk of death after surgery 
than those with a weak or negative SLC39A6 expres-
sion (P =  0.009, Fig.  4b). Furthermore, when the ESCC 
patients were stratified according to clinical stage, the 
survival rates of patients with SLC39A6 overexpression 
cancer were significantly lower than those of patients 
with SLC39A6 down-expression in early stage ESCC 
(P = 0.036, Fig. 4c). By contrast, SLC39A6 was not related 
to ESCC survival in later stage ESCC (P = 0.273, Fig. 4d).
To identify independent prognostic factors for ESCC 
survival, univariate and multivariate Cox regres-
sion models were used. Univariate Cox proportional 
hazard regression analysis revealed that lymph node 
metastasis [hazard ratio (HR)  =  2.315, 95  % CI 1.226–
4.371, P  =  0.010], clinical stage (HR  =  2.146, 95  % CI 
1.134–4.063, P  =  0.019), and SLC39A6 (HR  =  2.780, 
95  % CI 1.230–6.281, P =  0.014) were significant prog-
nostic predictors for OS of ESCC patients in the entire 
population (Table  5). Other clinicopathological param-
eters, including gender, age, and differentiation, were 
not prognostic factors for OS in our study (Table 5). Fur-
thermore, it appears that SLC39A6 protein was an inde-
pendent prognostic factor of ESCC (HR = 2.536, 95 % CI 
1.079–5.962, P =  0.033) in the multivariate Cox regres-
sion models (Table 5). Together, these data indicate that 
SLC39A6 overexpression was a significant independent 
prognostic factor for poor prognosis in ESCC and could 
thus be used as a potential biomarker for prognosis eval-
uation in patients with ESCC.
Downregulation of SLC39A6 suppresses ESCC cell growth 
and induces apoptosis
To ascertain that SLC39A6 is essential for esophageal 
cancer cell proliferation, we used siRNAs to deplete 
SLC39A6 protein in ESCC cells. Western blot analysis 
demonstrated an efficient knockdown of over 60  % of 
SLC39A6 protein expression after 72  h of transfection 
of siRNA against SLC39A6 in a dose-dependent manner 
but not by control siRNA in Eca109 and EC9706 cell lines 
(Fig.  5a, b). Cell growth was analyzed using MTT assay 
to determine whether downregulation of SLC39A6 has 
an inhibitory effect on ESCC cell proliferation. Growth 
curves demonstrated that growth of SLC39A6 siRNA-
mediated cells was significantly inhibited compared with 
that of the control group (Fig. 5c, d). For the colony for-
mation assay, the colonies from SLC39A6 siRNA-medi-
ated cells were much smaller than those from the control 
cells (Fig. 5e), and the number of colonies decreased by 
an average of four- to eightfold in ECA109 and EC9706 
cells compared with that in the control cells (P  <  0.05, 
n = 3, Fig. 5f ).
We performed flow cytometric analysis using Annexin 
V + (early apoptosis marker) and Annexin V +/PI + (late 
apoptosis) cells to investigate the effect of SLC39A6 
knockdown on apoptosis. As shown in Fig.  5g–i, the 
results show a higher frequency of cells programmed 
for both early and late phases of apoptosis in SLC39A6 
knockdown cells compared with that in vector controls. 
Table 2 SLC39A6 protein expression during cancer progression by IHC analysis in Chinese Han population
Cancer progression Immunostaining P value
Low High
Normal esophageal epithelium① 113 (85.61) 19 (14.39) ①:②P < 0.001; ①:③P < 0.001
Low grade intraepithelial neoplasia② 39 (48.15) 42 (51.85) ②:③P = 0.004; ②:④P = 0.037,
High grade intraepithelial neoplasia③ 12 (23.08) 40 (76.92) ③:④P = 0.179
ESCC④ 47 (33.10) 95 (66.90) ①:④P < 0.001
Table 3 Dysregulation frequency of  SLC39A6 protein 
expression in validation Cohorts





No. % No. %
SLC39A6 0.049
Nondysregulated 47 33.1 18 20.93
Dysregulated 95 66.9 68 79.07
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Fig. 2 Representative immunohistochemical staining of SLC39A6 in Kazakh ethnic. The negative controls for the normal tissues (a) and esophageal 
cancer (b) specimens (magnification ×100). Representative SLC39A6 immunostaining in non‑tumor esophageal (c) and esophagus squamous cell 
carcinoma (d) tissues with weak, moderate, or strong expression (top panel magnification ×40; middle panel magnification ×100; bottom panels 
magnification ×200). e Boxplot shows that SLC39A6 expression levels in ESCC are significantly higher than that in normal esophageal squamous 
epithelium from Kazakh population (p < 0.001). f Expression levels of SLC39A6 proteins were determined in esophageal carcinoma cell lines 
(Eca109, EC9706, TE‑1, and KYSE‑150) and a normal esophageal epithelium cell line (HEEC) using western blotting
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We observed an average increase of 5.39- and 9.57-fold 
in the early apoptosis rate in Eca-109-SLC39A6-siRNA 
and EC9706-SLC39A6-siRNA cells compared with that 
in negative control cells. The late apoptosis rate for these 
cells increased by 13.38- and 6.39-fold respectively, indi-
cating that downregulation of SLC39A6 promoted the 
apoptosis of ESCC cells.
SLC39A6 induce the EMT phenotype and increases ESCC 
cells invasiveness
Cancer metastasis is associated with EMT. To investigate 
whether SLC39A6 regulates EMT in esophageal cancer 
cells, the epithelial cell marker E-cadherin and mesen-
chymal marker vimentin were examined in Eca109 cell 
transfected with SLC39A6-siRNA and controls using the 
western blot. The epithelial marker E-cadherin was sig-
nificantly upregulated, whereas the mesenchymal mark-
ers vimentin was significantly reduced in Eca109 cells 
with knockdown of SLC39A6 compared with the con-
trols siRNA groups (Fig.  6a). In addition, cell morphol-
ogy examination indicated that knockdown of SLC39A6 
resulted in morphological changes in Eca109 cells 
(Fig. 6b).
In the reciprocal experiments, we examined whether 
knocking down SLC39A6 would inhibit ESCC cell inva-
siveness using SLC39A6 siRNA. As shown in Fig.  6c, 
ESCC cell invasive ability significantly decreased in 
SLC39A6-siRNA-treated cells compared with the 
control siRNA groups. The number of cells that invaded 
the Matrigel membrane was significantly lowered in 
SLC39A6-siRNA-treated cells compared with that in the 
control groups (P < 0.01) (Fig. 6d).
Discussion
A multistage process has been proposed for the evolution 
of ESCC, in which normal squamous epithelia undergo 
a series of histological and genetic progression towards 
noninvasive precursor lesions, and then towards inva-
sive cancer. Although a variety of molecular alterations 
have been identified over the last two decades, sensitive 
and specific biomarkers for early diagnosis and accurate 
indicators for ESCC prognosis are currently unavailable. 
Therefore, identification of targets for early detection of 
ESCC is important to improve the prognosis of patients 
with this pernicious disease. The key finding in this 
report lies in, for the first time, SLC39A6 protein level 
was both elevated in Chinese Han and Kazakh ethnic 
patients with ESCC, and this finding was also observed 
in precursor lesions tissues. In addition, in  vivo assays 
indicated the biological role of SLC39A6 in promoting 
anti-apoptosis and invasiveness by inducing the EMT 
phenotype of ESCC, further cementing that targeting 
of SLC39A6 might be potential therapeutic strategy for 
blocking ESCC.
SLC39A6, a member of a new subfamily of zinc trans-
porters, is involved in maintaining the intracellular 
Table 4 The correlations between SLC39A6 protein expression and clinicopathologic characteristics in Kazakh and Han 
ethnic
P < 0.05 indicates a significant association among the variables
a Well-differentiation vs. moderate differentiation + poor differentiation
Variables SLC39A6 expression in Han ethnic SLC39A6 expression in Kazakh ethnic
Total cases Low n (%) High n (%) P value Total cases Low n (%) High n (%) P value
Gender 0.863 0.621
 Male 107 35 (32.71) 72 (67.29) 53 12 (22.64) 41 (77.36)
 Female 35 12 (34.29) 23 (65.71) 33 6 (18.18) 27 (81.82)
Age (years) 0.254 0.113
 ≤60 57 22 (38.60) 35 (61.40) 53 14 (26.42) 39 (73.58)
 >60 85 25 (29.41) 60 (70.59) 33 4 (12.12) 29 (87.88)
Differentiationa 0.018 0.003
 Well 39 20 (51.28) 19 (48.72) 21 10 (47.62) 11 (52.38)
 Moderate 74 19 (25.68) 55 (74.32) 53 6 (11.32) 47 (88.68)
 Poor 29 8 (27.59) 21 (72.41) 12 2 (16.67) 10 (83.33)
Lymph node metastasis 0.050 0.690
 No 93 36 (38.71) 57 (61.29) 37 7 (18.92) 30 (81.08)
 Yes 49 11 (22.45) 38 (77.55) 49 11 (22.45) 38 (77.55)
TNM stage 0.276 0.026
 I + II 94 34 (36.17) 60 (63.83) 53 7 (13.21) 46 (86.79)
 III + IV 48 13 (27.01) 35 (72.99) 33 11 (33.33) 22 (66.67)
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homeostasis of zinc, an ion that is essential in the con-
trol of gene transcription, differentiation, development 
and growth, suggesting that its altered distribution 
might promote tumorigenesis [12, 21]. Accumulating 
evidence demonstrated that SLC39A6 may be linked to 
carcinogenic processes. Previous studies have shown that 
SLC39A6 is overexpressed in breast, prostate, pancreatic, 
cervical, and liver cancers [15–18, 22]. In ESCC, a previ-
ous study showed that SLC39A6 overexpression in Chi-
nese Han ethnic ESCC patients is a susceptibility gene 
for ESCC in a Chinese Han population [10]. However, 
whether SLC39A6 expression is increased in precursor 
lesions of ESCC and other ESCC patients of different eth-
nicities needs further exploration. Herein, we firstly dem-
onstrated that SLC39A6 protein expression increased 
progressively from NEE to LGIN to ESCC, and peaked 
in HGIN in the Han ethnic cohort. We further analyzed 
the relationship between SLC39A6 protein expression 
and outcome of patients with ESCC. Our results show 
that patients with higher SLC39A6 expression in ESCC 
Fig. 3 Receiver operating characteristic curve analysis for SLC39A6 immunohistochemical scores for detecting precancerous lesions and ESCC tis‑
sues. a Kazakh ethnic ESCC tissues. b Han ESCC tissues. c HGIN tissues. d LGIN tissues. The AUC in Kazakh ESCC, Han ethnic ESCC, HGIN, and LGIN is 
0.853, 0.78, 0.822, and 0.743, respectively
Page 11 of 16Cui et al. J Transl Med  (2015) 13:321 
Fig. 4 Kaplan–Meier survival curves for patients with overexpressed SLC39A6 and those with low SLC39A6 levels. a ESCC patients with overex‑
pressed SLC39A6 (IS ≥ 5) experienced a significantly shorter survival period after surgery than those with low SLC39A6 levels (IS < 5) (p < 0.01). b 
Patients with SLC39A6 overexpression had a greater risk of death than those with lower SLC39A6 levels (p < 0.01). c, d Patients with high SLC39A6 
expression shows the worse overall survival at stage I + II than those with low‑expression (p < 0.05)
Table 5 Univariate and multivariate Cox regression analyses of the prognostic variables in ESCC patients
Significant difference that 95 % CI of HR was not including
HR hazard radio, CI confidence interval
Variables Univariate analysis Multivariate analysis
HR 95 % CI P value HR 95 % CI P value
SLC39A6 expression 2.780 1.230 6.281 0.014 2.536 1.079 5.962 0.033
Gender (female) 1.400 0.706 2.773 0.335 1.522 0.734 3.157 0.259
Age (>60 years) 0.843 0.443 1.602 0.601 0.914 0.466 1.79 0.793
Differentiation (moderate) 0.798 0.314 2.027 0.636 0.963 0.370 2.509 0.939
Differentiation (poor) 0.886 0.393 1.998 0.770 0.879 0.373 2.072 0.768
Lymph node metastasis (yes) 2.315 1.226 4.371 0.010 2.129 0.611 7.412 0.235
TNM stage (III + IV) 2.146 1.134 4.063 0.019 1.034 0.303 3.523 0.958
Page 12 of 16Cui et al. J Transl Med  (2015) 13:321 
tissues had a worse prognosis than those with lower 
SLC39A6 expression. Cox regression analysis confirmed 
that SLC39A6 expression was an independent prognostic 
factor for poor OS in ESCC. All these results indicate that 
SLC39A6 overexpression could increase immediately 
when the esophageal squamous epithelium changed, as 
an “early” and “intermediate” event in the ESCC malig-
nant progression, indicating that SLC39A6 could serve 
as early detector of high-risk subjects and prognostic 
biomarker. Similarly, SLC39A6 protein was significantly 
overexpressed in Kazakh ethnic ESCC compared with 
that in NEE. Although the two ethnic groups had differ-
ent customs, cultural backgrounds, and food habits, in 
our study, overexpression of SLC39A6 was observed in 
both Han and Kazakhs ESCC tissues. This finding was in 
agreement with the findings in a Chinese Han population 
Fig. 5 Knockdown of SLC39A6 inhibits cell growth and enhances cell apoptosis in vitro. a, b Eca‑109 and EC9706 cells were transfected with 
either SLC39A6‑siRNA or control siRNA after 72 h, the cells were collected, and total cellular protein was used for western blotting analysis with 
anti‑SLC39A6 antibody as described. β‑actin served as an internal control. c, d Silencing endogenous SLC39A6 inhibits cell growth as determined 
by MTT assays. e Silencing endogenous SLC39A6 inhibits cell growth as determined by colony formation assays. f The histograms indicate that 
the number of colonies formed by cells treated with SLC39A6 siRNA was far fewer than that of control siRNA‑treated cells (*p < 0.05; **p < 0.01). 
g, h Cell apoptosis was detected by Annexin‑V/propidium iodide combined labeling flow cytometry in Eca‑109 and EC9706 cells upon inhibition 
of SLC39A6 protein. Flow cytometry analysis shows a large increase in the percentage of cells programmed for apoptosis in Eca‑109‑siRNA and 
EC9706‑siRNA cells comparing to the corresponding negative controls. i Statistics of the results in (g) and (h). *p < 0.05, versus scramble control 
(Student’s t test). Error bars represent mean ± SD from three independent experiments
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by Wu et  al. [10], which supported the hypothesis that 
SLC39A6 may function as an oncogene in ESCC patients 
from the two ethnic groups, Han and Kazakhs. To our 
knowledge, this study is the first report on the SLC39A6 
protein in the precursor lesions of ESCC and Kazakh 
populations.
Interestingly, in the present study, we also made an 
observation that SLC39A6 is expressed as a pro-protein 
(103 kDa) in inactive and active forms (68 kDa) in all of 
the esophageal cell lines. This result is consistent with 
that observed by Taylor et  al. [20] in breast cancer cell 
lines; Taylor KM et al. [20] found three SLC39A6 protein 
bands, particularly those at 103, 68, and 35  kDa; these 
bands are obtained because of the N-terminal proteo-
lytic cleavage of SLC39A6 by using three anti-SLC39A6 
antibodies. SLC39A6 is modified via N-terminal cleavage 
before this protein relocates to the plasma membrane in 
breast cancer. However, whether SLC39A6 is activated 
via N-terminal cleavage in esophageal cancer should be 
clarified in future studies.
The role of zinc in cell growth, division, and differen-
tiation, as well as basal homeostasis, is of key importance 
[13]. Loss of terminal differentiation is one of the char-
acteristics of ESCC cells, even in the well-differentiated 
cases, and the differentiation methods of cancer cells 
were quite different from those of normal non-kerati-
nised squamous epithelium. We have, for the first time, 
independently observed that high SLC39A6 expres-
sion in Han and Kazakh patients with ESCC was asso-
ciated with poor differentiation. Changes in cellular 
Fig. 6 SLC39A6 promotes the EMT phenotype and inhibition of SLC39A6 expression diminished invasion capacity of Eca109 and EC9706 cells. a 
SLC39A6‑siRNA was transfected into Eca109 and EC9706 cells for 72 h and cells were harvested for an immunoblot analysis of vimentin and E‑cad‑
herin. Silencing SLC39A6 was accompanied by the increased expression of E‑cadherin and loss of vimentin, which are all hallmarks of EMT markers. 
Knockdown of SLC39A6 results in morphological changes in Eca109 cell. b Photographs were taken using a Nikon microscope (phase contrast). 
Original magnification ×200. c Cell invasion assay was performed using Matrigel‑coated transwell plates for Eca109 and EC9706 cells. Knockdown 
of SLC39A6 significantly reduced cell invasiveness in the two esophageal cancer cell lines compared with that in SLC39A6‑siRNA controls. d The 
relative percentage of cells passing through a Matrigel filter (**p < 0.01). All experiments were performed at least three times with consistent and 
repeatable results
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zinc concentrations in various types of cancers [23] are 
likely the result of alterations in the expression of zinc 
transporters [24–26]. Thus, we speculate that increased 
SLC39A6 promotes the loss of terminal differentiation 
in normal non-keratinized squamous epithelium. We 
also observed that high SLC39A6 expression in Kazakh 
patients was associated with TNM stage, but differ from 
those in Han. This discrepancy may be due to several fac-
tors, of which sample size may be one as Kazakh cohort 
had a smaller sample size (n = 82) than the Han cohort 
(n = 142). The other possible factors resulting in the dis-
crepancy may be population heterogeneity and genetic 
backgrounds of different ethnicities, which need to fur-
ther clarified in studies using uniform ethnic groups with 
larger sample sizes.
SLC39A6 is involved in maintaining the intracellu-
lar homeostasis of zinc, an ion that is essential for cell 
proliferation and tumor growth [12, 21]. The cell prolif-
erating effects of growth factors are accompanied with 
an increase in the concentrations of labile zinc [13]. 
Here, indirectly consistent with these previous reports, 
we found that knockdown of SLC39A6 expression sig-
nificantly reduced proliferation and promoted ESCC 
cell apoptosis. Our findings were in consistent with 
those of Betty et al., who found that dietary zinc deple-
tion is effective in retarding tumor growth even with 
well-established tumors [27]. However, the mechanism 
by which SLC39A6 induces the proliferation of ESCC 
remains unclear. Indirect evidence from Chen et  al., 
confirmed that more zinc-deficient cells remain in the S 
phase and do not undergo mitosis compared with zinc-
sufficient cells, with cell proliferation being attenuated 
based on cell cycle studies [28]. Our studies indicate that 
the targeting of SLC39A6 might be potential therapeu-
tic strategy for blocking ESCC proliferation by restric-
tion specific minerals, such as zinc, via knockdown of 
SLC39A6.
Invasion and metastasis are two of the most important 
hallmarks of cancer [23]. SLC39A6 has been reported 
to be a downstream target of signal transducer and acti-
vator of transcription 3 (STAT3). It plays a critical part 
in gastrula organizer cells undergoing EMT by affect-
ing Snail activity [29]. SLC39A6 was linked to MET in 
breast cancer through SLC39A6-induced zinc influx 
when N-terminal cleavage inactivates GSK-3β; as a 
result, unphosphorylated Snail in the nucleus downregu-
lates the adherence genes, such as E-cadherin. Thus, cell 
rounding and detachment occur [20]. Considering the 
potential mechanism of the SLC39A6 in ESCC, we per-
formed in vitro functional analyses in the current study 
and showed that the suppression of the SLC39A6 expres-
sion modulated the malignant phenotype of ESCC cells, 
abrogated cell invasion, and induced an EMT phenotype 
in ESCC cell lines. The expression of E-cadherin, loss of 
vimentin, and morphological changes in ESCC cells were 
also enhanced in  vitro. EMT is a consistently observed 
phenomenon that is a vital aspect of embryogenesis 
and cancer progression [30]. During EMT, cancer cells 
lose their adhesion and begin the process of metasta-
sis [31]. SLC39A6 was shown to be a mediator down-
stream from the STAT3 and Snail, cooperating with 
Snail in the repression of epithelial marker E-cadherin 
gene transcription [29]. Given that the induction of EMT 
by ectopic expression of either the Twist or Snail tran-
scription factors generated stem cell-like cells [32], we 
proposed that SLC39A6 might regulate the stemness of 
esophageal cancer and promote the invasion of ESCC 
cells by affecting the expression of STAT3 and Snail, 
which needs further exploration.
However, it must be pointed out that we did not 
found SLC39A6 expression significantly differs between 
ESCC and their corresponding HGIN tissues; similarly, 
the SLC39A6 expression does not significantly differ 
between ESCC and their corresponding LGIN tissues 
(Additional file  3: Table S2), which was in conflict with 
the results provided in Table 2 between LGIN and ESCC 
(P  =  0.037). There could be multiple reasons contrib-
uted to the inconsistency in results. However, as all we 
known, it’s impossible for us to find the patients with 
only precancerous lesions. Thus, we selected the adja-
cent esophageal cancer tissues from the patients with 
ESCC diagnosed as HGIN or LGIN tissues to compare 
the SLC39A6 expression among the different character-
istics of the tissues, enhance the diagnostic value of the 
early detection of ESCC, and to clarify the function of 
SLC39A6 as a biomarker of the early detection of ESCC; 
nevertheless, this phenomenon is also the limitation of 
our research. The current results reveal the difference 
among HGIN, LGIN, and ESCC. To a certain degree, 
these results indicate that the SLC39A6 expression can 
be used as a marker to detect ESCC in early stages. How-
ever, we also acknowledge that the sampling selection in 
the present study has many limitations.
Conclusions
In summary, our study reveals that SLC39A6 was upreg-
ulated in the onset of ESCC. Thus, SLC39A6 may be 
a potential biomarker for early detection of high-risk 
subjects and early diagnosis of ESCC and an independ-
ent prognosis factor of ESCC. Moreover, knockdown 
of SLC39A6 expression modulated the malignant phe-
notype of ESCC cells, resulting in significantly reduced 
proliferation and invasion with MET phenotype in vitro. 
Combined, our findings highlight a tumor-promoting 
role for SLC39A6 in ESCC and targeting SLC39A6 might 
be a potential therapeutic strategy.
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